229 related articles for article (PubMed ID: 21243446)
1. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma.
Alapat DV; Ain KB; Sloan DA; Monaghan KG; Karabakhtsian RG
Endocrine; 2011 Apr; 39(2):148-52. PubMed ID: 21243446
[TBL] [Abstract][Full Text] [Related]
2. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma.
Bockhorn M; Frilling A; Rewerk S; Liedke M; Dirsch O; Schmid KW; Broelsch CE
Thyroid; 2004 Jun; 14(6):468-70. PubMed ID: 15242577
[TBL] [Abstract][Full Text] [Related]
3. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract][Full Text] [Related]
4. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
6. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
7. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers.
Giovanella L; Crippa S; Cariani L
Int J Biol Markers; 2008; 23(2):129-31. PubMed ID: 18629788
[TBL] [Abstract][Full Text] [Related]
8. Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.
Yip DT; Hassan M; Pazaitou-Panayiotou K; Ruan DT; Gawande AA; Gaz RD; Moore FD; Hodin RA; Stephen AE; Sadow PM; Daniels GH; Randolph GW; Parangi S; Lubitz CC
Surgery; 2011 Dec; 150(6):1168-77. PubMed ID: 22136837
[TBL] [Abstract][Full Text] [Related]
9. Genetic analysis of a hereditary medullary thyroid carcinoma case with normal preoperative serum calcitonin levels.
Zhang G; Jiang Y; Zhang S; Zhao L; Fan J; Zhang Z; Ma J; Chen R; Xu Y
Pathol Res Pract; 2019 Oct; 215(10):152529. PubMed ID: 31409511
[TBL] [Abstract][Full Text] [Related]
10. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.
Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R
Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.
Thomas CM; Asa SL; Ezzat S; Sawka AM; Goldstein D
Curr Oncol; 2019 Oct; 26(5):338-344. PubMed ID: 31708652
[TBL] [Abstract][Full Text] [Related]
13. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Kurzrock R; Atkins J; Wheler J; Fu S; Naing A; Busaidy N; Hong D; Sherman S
Ann Oncol; 2013 Sep; 24(9):2256-61. PubMed ID: 23676418
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin-negative neuroendocrine tumor of the thyroid: a distinct clinical entity.
Chernyavsky VS; Farghani S; Davidov T; Ma L; Barnard N; Amorosa LF; Trooskin SZ
Thyroid; 2011 Feb; 21(2):193-6. PubMed ID: 21275766
[TBL] [Abstract][Full Text] [Related]
15. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times.
Papapetrou PD; Polymeris A
Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112
[TBL] [Abstract][Full Text] [Related]
16. Brain metastasis from calcitonin-negative medullary thyroid carcinoma.
Baptista PF; Fonseca LCM; Carvalho AFC; Silva SNVD; Freitas CRO
Ann Endocrinol (Paris); 2022 Aug; 83(4):258-260. PubMed ID: 35537523
[TBL] [Abstract][Full Text] [Related]
17. Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
Gambardella C; Offi C; Patrone R; Clarizia G; Mauriello C; Tartaglia E; Di Capua F; Di Martino S; Romano RM; Fiore L; Conzo A; Conzo G; Docimo G
BMC Endocr Disord; 2019 May; 19(Suppl 1):45. PubMed ID: 31142313
[TBL] [Abstract][Full Text] [Related]
18. Serum calcitonin negative mixed medullary-follicular carcinoma initially diagnosed as medullary thyroid carcinoma by fine-needle aspiration cytology: A case report and review of the literatures.
Liu Y; Yuan L; Yang D; Jin Y
Diagn Cytopathol; 2018 Aug; 46(8):690-693. PubMed ID: 29524315
[TBL] [Abstract][Full Text] [Related]
19. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.
Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ
J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887
[TBL] [Abstract][Full Text] [Related]
20. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
Laure Giraudet A; Al Ghulzan A; Aupérin A; Leboulleux S; Chehboun A; Troalen F; Dromain C; Lumbroso J; Baudin E; Schlumberger M
Eur J Endocrinol; 2008 Feb; 158(2):239-46. PubMed ID: 18230832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
